(151 days)
Not Found
No
The summary does not mention AI, ML, deep learning, or any related terms. The device description focuses on traditional imaging modalities and a normative database for comparison, which is not indicative of AI/ML.
No
The device is a diagnostic imaging device intended for viewing, imaging, and measuring ocular anatomy and lesions, and as an aid in the detection and management of various ocular diseases. It does not provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states, "The Spectralis HRA+OCT is a non-contact ophthalmic diagnostic imaging device." It also mentions its purpose as "an aid in the detection and management of various ocular diseases."
No
The device description explicitly lists hardware components such as a laser scanning camera, camera mount with headrest, operation panel, power supply box, and host computer, in addition to the operation software.
Based on the provided information, the Spectralis HRA+OCT is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to provide information about a person's health.
- Spectralis HRA+OCT Function: The Spectralis HRA+OCT is a non-contact ophthalmic diagnostic imaging device that directly images the posterior segment of the eye. It does not analyze samples taken from the body. It uses light and optical principles to visualize and measure structures within the eye itself.
Therefore, while it is a diagnostic device used in a clinical setting, it falls under the category of in vivo diagnostic imaging devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
The Spectralis HRA+OCT is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three- dimensional imaging, cross-sectional imaging, fundus photography, and fluorescence imaging (fluorescein, indocyanine green and autofluorescence), and to perform measurements of ocular anatomy and ocular lesions. The device is indicated as an aid in the detection and management of various ocular diseases including: age-related macular degeneration, macular edema, diabetic retinopathy, retinal and choroidal vascular diseases, glaucoma, and for viewing geographic atrophy as well as changes in the eye that result from neurodegenerative diseases. The Spectralis HRA+OCT includes a retinal nerve fiber layer thickness normative database, which is used to quantitatively compare the retinal nerve fiber layer in the human retina to a database of Caucasian normal subjects; the classification result is valid only for Caucasian subjects.
Product codes
MYC, OBO
Device Description
The Spectralis HRA+OCT is a real-time imaging system of the posterior segment of the human eye and for aiding in the assessment and management of various diseases of the posterior segment, such as age-related macular degeneration, diabetic retinopathy, and glaucoma. The device is a combination of optical coherence tomography (OCT) with confocal scanning laser ophthalmoscopy (cSLO). OCT imaging includes high-resolution cross-sectional imaging of ocular structures (e.g., retina, macula, optic nerve head); cSLO imaging includes high-resolution and dynamic infrared reflectance, blue reflectance, fluorescein angiography, indocyanine green angiography, and autofluorescence imaging. OCT images and cSLO images are acquired simultaneously and are viewed side-by-side on the computer screen. Images are acquired and stored using Spectralis operation software, which runs on a standard personal computer. Spectralis components include a laser scanning camera, camera mount with headrest, operation panel, power supply box, operation software, and host computer.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
optical coherence tomography (OCT), confocal scanning laser ophthalmoscopy (cSLO)
Anatomical Site
posterior segment of the human eye
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
The normative database includes 201 subjects of Caucasian origin enrolled in a patient registry. Demographically, the subjects included: 111 male, 90 female, mean (SD) age 48.2 ± 14.5 years, age range 18 to 78 years. Included subjects had no history of glaucoma, normal intraocular pressure, normal visual field, normal appearance of optic disc, etc. Screening for entry into the study included patient history and physical examination to determine if eyes were "normal" by two ophthalmologists.
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance - Bench Testing:
The Spectralis HRA+OCT has been tested according to IEC 60601-1, IEC 60601-1-2, and IEC 60601-1-4 and was found to meet all requirements. The system is a laser product of Class 1 according to 21 CFR §1040.10 and complies with IEC 60825-1.
Accuracy testing was performed to determine the accuracy of measurements in the OCT images, as well as in the reflectance and angiography images. Results of this study confirmed accuracy of measured values compared to one another and compared to the true value, verifying that the performance of the Spectralis device is accurate and within stated specifications.
Performance - Clinical Evaluation:
Reproducibility and Repeatability: A study in human volunteers was conducted to ensure Repeatability and Reproducibility of Spectralis HRA+OCT device measurements. All possible measures were evaluated for the Spectralis HRA+OCT. For reproducibility and repeatability, the coefficients of variation of the measured endpoints were within the specified range for this device.
Normative Database: The normative database includes 201 subjects of Caucasian origin enrolled in a patient registry. If subjects had a normal examination and no medical history of ocular pathology, images were acquired and measurements were then made using the Spectralis HRA+OCT device per Instructions for Use to measure RNFL thickness. Results were compiled to form a normative database of RNFL thickness. The database is limited by a sample size of 201 subjects (1 case in the 70 years age group), Caucasian ethnicity, and inclusion of subjects with refractive errors in the range from +5 diopters to -7 diopters.
Agreement Study with Predicate: An agreement study was conducted to compare RNFL classification results from Spectralis HRA+OCT to results from Stratus in normal and glaucoma eyes. Healthy subjects (n=101) and glaucoma patients (n=183) were examined using Spectralis and Stratus. Results of this analysis indicate that there is a good linear correlation between RNFL thickness measurements with the Spectralis and Stratus devices for healthy and for glaucoma subjects and in all measurement regions. The slopes and intercepts of the regression lines are in the neighborhood of 1 and 0, respectively, although they vary in the different measurement regions. Because of these differences, Spectralis and Stratus RNFL thickness measurement results should not be used interchangeably.
Studies in Eyes with Disease: Case Reports and Case Series of eyes from patients with various pathologies were examined with Spectralis HRA+OCT and these images show that no artifacts were found and there were no unexpected RNFL thickness measurement results or unexpected classification results. RNFL thickness was found to be predictably decreased in glaucoma subjects.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
0
510(k) Summary
Manufacturer and Submitter
| Company Name: | Heidelberg Engineering GmbH | |
|---|---|---|
| Company Address: | Tiergartenstrasse 15 | |
| 69121 Heidelberg, Germany | ||
| phone: +49 / 6221 / 64 643 0 | ||
| fax: +49 / 6221 / 64 63 62 | 00 | |
| Contact Person: | Dr. Gerhard Zinser | |
| Date Summary Prepared: | September 27, 2010 |
1 1 2010
Device
| Trade/Device Name: | Spectralis™ HRA+OCT |
|---|---|
| Common/Usual Name: | Retina Angiograph / Optical Coherence Tomograph |
| Classification Name: | Ophthalmoscope, AC-powered |
| Regulation Number: | 21 CFR 886.1570 |
| Product Code: | MYC, OBO |
| Classification Panel: | Ophthalmic |
| Classification: | Class II |
Device Description
The Spectralis HRA+OCT is a real-time imaging system of the posterior segment of the human eye and for aiding in the assessment and management of various diseases of the posterior segment, such as age-related macular degeneration, diabetic retinopathy, and glaucoma. The device is a combination of optical coherence tomography (OCT) with confocal scanning laser ophthalmoscopy (cSLO). OCT imaging includes high-resolution cross-sectional imaging of ocular structures (e.g., retina, macula, optic nerve head); cSLO imaging includes high-resolution and dynamic infrared reflectance, blue reflectance, fluorescein angiography, indocyanine green angiography, and autofluorescence imaging. OCT images and cSLO images are acquired simultaneously and are viewed side-by-side on the computer screen. Images are acquired and stored using Spectralis operation software, which runs on a standard personal computer. Spectralis components include a laser scanning camera, camera mount with headrest, operation panel, power supply box, operation software, and host computer.
Intended Use/Indications for Use
The Spectralis HRA+OCT is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging, fundus photography, and fluorescence imaging (fluorescein, indocyanine green and autofluorescence), and to perform measurements of ocular anatomy and ocular lesions. The device is indicated as an aid in the detection and management of various ocular diseases including: age-related macular degeneration, macular edema, diabetic retinopathy, retinal and choroidal vascular diseases, glaucoma, and for viewing geographic atrophy as well as changes in the eye that result from neurodegenerative diseases. The Spectralis HRA+OCT includes a retinal nerve fiber layer thickness normative database, which is used to quantitatively compare the retinal nerve fiber layer in the human retina to a database of Caucasian normal subjects; the classification result is valid only for Caucasian subjects.
l
1
Substantial Equivalence Analysis
The Spectralis HRA+OCT has the same intended use and basic technological characteristics as the Heidelberg HRA2/OCT (K063191). The device has been updated to include new optical layout and components, new electronic components, new mechanical design, and new software including the addition of a normative database for RNFL thickness. These differences do not adversely affect safety or effectiveness, as verified with clinical and bench testing. Predicate devices incorporating similar technology features to the upgraded Spectralis device include: the STATUS OCT with Retinal Nerve Fiber Layer Normative Database (K030433) for the similarity in having a normative database, and the IRI Integrated Retinal Imager (K062295) for the autofluorescence intended use.
Performance - Bench Testing
The Spectralis HRA+OCT has been tested according to IEC 60601-1, IEC 60601-1-2, and IEC 60601-1-4 and was found to meet all requirements. The system is a laser product of Class 1 according to 21 CFR §1040.10 and complies with IEC 60825-1.
Accuracy testing was performed to determine the accuracy of measurements in the OCT images, as well as in the reflectance and angiography images. Results of this study confirmed accuracy of measured values compared to one another and compared to the true value, verifying that the performance of the Spectralis device is accurate and within stated specifications.
Performance - Clinical Evaluation
Reproducibility and Repeatability
A study in human volunteers was conducted to ensure Repeatability and Reproducibility of Spectralis HRA+OCT device measurements. All possible measures were evaluated for the Spectralis HRA+OCT. For reproducibility and repeatability, the coefficients of variation of the measured endpoints were within the specified range for this device.
Normative Database
The normative database includes 201 subjects of Caucasian origin enrolled in a patient registry. Demographically, the subjects included: 111 male, 90 female, mean (SD) age 48.2 ± 14.5 years, age range 18 to 78 years. Included subjects had no history of glaucoma, normal intraocular pressure, normal visual field, normal appearance of optic disc, etc. Screening for entry into the study included patient history and physical examination to determine if eyes were "normal" by two ophthalmologists.
If subjects had a normal examination and no medical history of ocular pathology, images were acquired and measurements were then made using the Spectralis HRA+OCT device per Instructions for Use to measure RNFL thickness. Results were compiled to form a normative database of RNFL thickness. The database is limited by a sample size of 201 subjects (1 case in the 70 years age group), Caucasian ethnicity, and inclusion of subjects with refractive errors in the range from +5 diopters to -7 diopters.
Normative database limitations described above should be considered when examining subjects whose characteristics differ from those included in the database.
2
RNFL thickness measurements made with the Spectralis HRA +OCT are compared to the normative database. For that purpose, an age-adjustment of the normal database is performed and percentile limits of the normal distribution are computed as follows.
For each subject in the normative database, RNFL thickness at each point along the circle scan, mean RNFL thickness along the whole circle scan (global), and mean RNFL thickness within certain sectors of the circle scan (temporal, temporal-inferior, temporal-inferior, nasal, nasalsuperior, nasal-inferior) were measured. From these measurements, the age-adjusted percentiles of the database sample of 201 healthy Caucasians were determined. These age-adjusted percentiles form the basis for highlighting a result as being within or outside the normal limits (greater than the 5th or less than the 1st percentile of the database sample). The meaning of the nth percentile is that n percent of normal Caucasian subjects from the database sample have a RNFL thickness of less than or equal to this value.
Age-adjustment of the normal data is based on the linear regression of RNFL thickness vs. age of the normal subjects. Global RNFL thickness and RNFL thickness in the sectors temporal, temporal-superior, temporal-inferior, and nasal-inferior showed negative slopes (decrease of RNFL thickness) with age in the normal data and are adjusted. RNFL thicknesses in the sectors nasal and nasal-superior showed insignificant positive slopes with age in the normal data and are not adjusted.
As an example for the effect of age, the following tables show the values of the 1st and 5th percentile of RNFL thickness global and in the six sectors for ages 45 and 65 years. All values are in microns; the numbers in brackets represent the 95% confidence intervals of the respective percentiles.
| Age 15 years | ||
|---|---|---|
| 1st percentile (95% CI) | 5th percentile (95% CI) | |
| Global | 76.0 (73.2 - 78.2) | 82.1 (79.9 - 83.9) |
| sector T | 46.9 (42.8 - 49.5) | 54.9 (51.7 - 57.0) |
| sector TS | 96.3 (90.8 - 100.0) | 107.4 (103.1 - 110.4) |
| sector TI | 99.1 (92.7 - 103.1) | 111.6 (106.6 - 115.0) |
| sector N | 38.3 (34.0 - 42.0) | 48.1 (44.6 - 51.0) |
| sector NS | 57.8 (52.0 - 62.6) | 70.7 (66.1 - 74.6) |
| sector NI | 53.6 (46.7 - 59.2) | 68.8 (63.4 - 73.3) |
Age 45 vears
Age 65 years
| 1st percentile (95% CI) | 5th percentile (95% CI) | |
|---|---|---|
| Global | 74.5 (71.7 - 76.7) | 80.6 (78.4 - 82.4) |
| sector T | 43.9 (39.8 - 46.5) | 52.0 (48.8 - 54.1) |
| sector TS | 93.0 (87.6 - 96.8) | 104.1 (99.8 - 107.2) |
| sector TI | 94.6 (88.2 - 98.6) | 107.1 (102.1 - 110.4) |
| sector N | 38.3 (34.0 - 42.0) | 48.1 (44.6 - 51.0) |
| sector NS | 57.8 (52.0 - 62.6) | 70.7 (66.1 - 74.6) |
| sector NI | 51.9 (45.0 - 57.5) | 67.2 (61.7 - 71.7) |
3
3
Agreement Study with Predicate
An agreement study was conducted to compare RNFL classification results from Spectralis HRA+OCT to results from Stratus in normal and glaucoma eyes. Healthy subjects (n=101) and glaucoma patients (n=183) were examined using Spectralis and Stratus. Results of this analysis indicate that there is a good linear correlation between RNFL thickness measurements with the Spectralis and Stratus devices for healthy and for glaucoma subjects and in all measurement regions. The slopes and intercepts of the regression lines are in the neighborhood of 1 and 0, respectively, although they vary in the different measurement regions. Because of these differences, Spectralis and Stratus RNFL thickness measurement results should not be used interchangeably. (This is in agreement with the published literature.)
Studies in Eyes with Disease
Case Reports and Case Series of eyes from patients with various pathologies were examined with Spectralis HRA+OCT and these images show that no artifacts were found and there were no unexpected RNFL thickness measurement results or unexpected classification results. RNFL thickness was found to be predictably decreased in glaucoma subjects.
4
Image /page/4/Picture/1 description: The image shows a logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of three human figures, arranged in a way that resembles a bird in flight. The figures are black against a white background. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the figures.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Heidelberg Engineering GmbH c/o Diane Mandell-Horwitz, Ph.D., RAC Official Correspondent and Consultant The Weinberg Group, Inc. 1220 Nineteenth St., NW, Suite 300 Washington, D.C., 20036
OCT 01 2010
Re: K101223
Trade/Device Name: Spectralis™ HRA + OCT Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope, AC-Powered Regulatory Class: II Product Code: OBO, MYC Dated: September 29, 2010 Received: September 29, 2010
Dear Dr. Mandell-Horwitz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing
5
Page 2 - Dr. Mandell-Horwitz
(21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Kesia Alexander
Malvina B. Eydelman, M.D. Director Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known): K101223
Device Name:
Spectralis™ HRA+OCT
Indications For Use:
The Spectralis HRA+OCT is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and threedimensional imaging, cross-sectional imaging, fundus photography, and fluorescence imaging (fluorescein, indocyanine green and autofluorescence), and to perform measurements of ocular anatomy and ocular lesions. The device is indicated as an aid in the detection and management of various ocular diseases including: age-related macular degeneration, macular edema, diabetic retinopathy, retinal and choroidal vascular diseases, glaucoma, and for viewing geographic atrophy as well as changes in the eye that result from neurodegenerative diseases. The Spectralis HRA+OCT includes a retinal nerve fiber layer thickness normative database, which is used to quantitatively compare the retinal nerve fiber layer in the human retina to a database of Caucasian normal subjects; the classification result is valid only for Caucasian subjects.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel Kausen M.D.
(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices
510(k) Number K101223